A soluble LAG-3 protein as an immunopotentiator for therapeutic vaccines: Preclinical evaluation of IMP321

Vaccine
Sylvie FougerayF Triebel

Abstract

A soluble LAG-3 (CD223) molecule (sLAG-3) is a natural high affinity ligand for MHC class II. It is known to induce maturation of monocyte-derived dendritic cells in vitro and is used as a vaccine adjuvant to induce CD4 Th1 and CD8 T cell responses in vivo. The work presented herein was performed to study the biological activity of a preclinical grade human sLAG-3 protein, called IMP321: (i) binding on murine APC, (ii) induction of dendritic cell maturation, (iii) safety of repeated injections in mice. The results show that IMP321 binds MHC class II(+) murine APC, induces the maturation of dendritic cells and is well tolerated either injected alone or as an adjuvant with strongly immunogenic antigens.

References

Jun 6, 2002·Journal of the National Cancer Institute·Giorgio ParmianiAndrea Anichini
Jul 13, 2002·European Journal of Immunology·Christian LienhardtGianfranco Del Prete
Feb 8, 2005·The Journal of Clinical Investigation·Daniel E SpeiserPedro Romero
Jun 14, 2005·Nature Medicine·Vladimir P BadovinacJohn T Harty

❮ Previous
Next ❯

Citations

Feb 2, 2013·Nature Reviews. Drug Discovery·Sheng YaoLieping Chen
Sep 12, 2015·Acta Oncologica·Xiaodong LiChangping Wu
Jun 5, 2007·Expert Review of Vaccines·Clint S SchmidtNadeem A Sheikh
Jun 15, 2016·Cancer Science·Yayi HeFred R Hirsch
Apr 28, 2017·Expert Opinion on Biological Therapy·Mariela A Moreno AyalaMarianela Candolfi
Dec 15, 2010·Expert Opinion on Therapeutic Targets·Sophie SierroDaniel E Speiser
Nov 7, 2019·Molecular Cancer·Shuang QinSuxia Luo
Sep 6, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Chrystelle BrignoneFrédéric Triebel
Mar 31, 2018·Frontiers in Immunology·Maarten VerstevenEva Lion
Feb 11, 2020·Frontiers in Oncology·Bella S GuerrouahenEmmanuel T Akporiaye
Oct 27, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amandine LegatDaniel E Speiser
Sep 17, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chrystelle BrignoneFrédéric Triebel
Nov 10, 2020·Frontiers in Immunology·Rossana FranzinElena Ranieri
Mar 3, 2021·Current Rheumatology Reports·Stinne Ravn Greisen, Bent Deleuran
Dec 1, 2020·Pharmacology & Therapeutics·Bingjian WenZhengquan Su

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.